Fig. 6: Fenofibrate did not reduce NAFLD features in Acot12−/− mice.
From: Loss of Acot12 contributes to NAFLD independent of lipolysis of adipose tissue
a Representative H&E staining of Acot12+/+ and Acot12−/− mouse livers administered vehicle (corn oil) or fenofibrate (FF, 100 mg/kg). n = 3–4 per mice group. Scale bars, 100 μm. b Representative ORO staining in Acot12+/+ and Acot12−/− mouse livers administered vehicle or FF. Scale bars, 100 μm. c Representative filipin staining in Acot12+/+ and Acot12−/− mouse livers administered vehicle or FF. Scale bars, 100 μm. d Liver weight and the ratio of liver weight to body weight in vehicle- or FF-administered HFHCD Acot12+/+ or Acot12−/− mice. e Hepatic TG, TC, FFA, and acetyl-CoA levels in Acot12+/+ and Acot12−/− mouse livers administered vehicle or FF. f Expression levels of Acot12 and Ppara in Acot12+/+ and Acot12−/− mouse livers administered vehicle or FF. g Expression levels of cholesterol biosynthesis genes in Acot12+/+ and Acot12−/− mouse livers administered vehicle or FF (n = 3–4 mice per group). h Expression levels of lipogenic genes in Acot12+/+ and Acot12−/− mouse livers administered vehicle or FF (n = 3–4 mice per group). All data are presented as the mean ± SEM. Statistical differences among four groups were performed using one-way ANOVA (d, e, g, h) followed by Tukey’s multiple comparison test or multiple t test, followed by Holm–Sidak’s multiple comparison test (f). n.s. nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
